Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants
Revista Española de Quimioterapia · 2024
DOI: 10.37201/req/026.2024 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Revista Española de Quimioterapia, 2024. Verfasst von R Rodríguez-Fernández und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rosa Rodriguez-Fernández. Sección de Pediatría Interna Hospitalaria. Servicio de Pediatría. Hospital Gregorio Marañón. Calle O'Donnell 50, 28007, Mad…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Hospitalization, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction. Respiratory syncytial virus (RSV) bronchiolitis is the leading cause of hospitalization in infants. This season, a long half-life monoclonal antibody (Nirsevimab) is available to prevent this disease for all infants born from 1 April-30 September to 2023 and all those born during RSV season (October2023- March 2024). The aim of this study was to evaluate the impact of the implementation of this antibody on RSV admissions in a tertiary hospital. Material and methods. Observational, retrospective and analytical study. All patients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rosa Rodriguez-Fernández. Sección de Pediatría Interna Hospitalaria. Servicio de Pediatría. Hospital Gregorio Marañón. Calle O'Donnell 50, 28007, Madrid, Spain. rrfernandez@salud.madrid.org.
Zitieren
APA
Rodríguez-Fernández, R., González-Martínez, F., Ojeda Velázquez, I., Rodríguez Díaz, M., Capozzi Bucciol, M. V., González-Sánchez, M. I., Pérez-Moreno, J., & Toledo Del Castillo, B. (2024). Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants. Revista Española de Quimioterapia. https://doi.org/10.37201/req/026.2024
Vancouver
Rodríguez-Fernández R, González-Martínez F, Ojeda Velázquez I, Rodríguez Díaz M, Capozzi Bucciol MV, González-Sánchez MI, et al. Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants. Revista Española de Quimioterapia. 2024. doi:10.37201/req/026.2024
BibTeX
@article{RodrguezFernndez2024,
author = {Rodríguez-Fernández, R and González-Martínez, F and Ojeda Velázquez, I and Rodríguez Díaz, M and Capozzi Bucciol, M V and González-Sánchez, M I and Pérez-Moreno, J and Toledo Del Castillo, B},
title = {Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants},
journal = {Revista Española de Quimioterapia},
year = {2024},
doi = {10.37201/req/026.2024}
}
EUVIMED